The tumor microenvironment: a pitch for multiple players

Giovanna Schiavoni, Lucia Gabriele and Fabrizio Mattei *

Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy

THE TUMOR MICROENVIRONMENT: RESIDENT AND NON-RESIDENT POPULATIONS

Similarly to the majority of normal tissues, solid tumors are composed by two distinct compartments, the parenchyma and the stroma. The parenchyma is representative of cancer cells themselves, whereas all non-malignant cells and the other connective tissue elements belong to the stromal compartment (Dvorak et al., 2011). The stroma is a very heterogeneous milieu including various cell types and adhesion molecules, both contributing to the functional activity and structural support of the tumor microenvironment itself. Thus, the stromal and parenchymal regions may often be indistinguishable. For this reason, we can conveniently subdivide the cancer microenvironment into non-resident and resident components (Table 1).

Through this definition the resident component comprises cell populations and structural factors stably resident within the milieu of the stroma. In particular, endothelial cells and pericytes are resident cellular components surrounding and composing the blood vessels. Pericytes are structural cell components of blood vessels whose importance has been recently defined relatively to the cancer environment. Pericytes are commonly present in several organs and multicellular structures (Fernandez-Klett et al., 2012; Iwasaki et al., 2012; Hellerbrand, 2013; Ren et al., 2013). Of interest, a functional role for these structures has been recently reported in the activation of innate immunity (Stark et al., 2013). In addition, pericytes can also display a functional property in cancer progression. This was shown in a study employing a transgenic mouse model expressing the viral thymidine kinase (tk) under control of the NG2 promoter (NG2-tk mice) and transplanted with 4T1 breast cancer cells. In this work, Cooke et al. (2012) reported that treatment with Ganciclovir induced depletion of pericytic structures in tumors from NG2-tk mice but not in those from control mice, that was associated with markedly increased breast cancer progression and metastatic potential in mutant animals. The mesenchyma is another macrostructure belonging to the resident components, and is composed by several cellular types constantly present in this environment, such as fibroblasts, mesenchymal cells, and cancer stem cells (CSC). Other structural components such as adhesion molecules, cytokines, chemokines, and other biological compounds of functional relevance are all essential and confer to mesenchyma a time- and space-dependent functional role for the expansion of the tumor mass.

Belonging to the non-resident constituent are different immune cell populations with the ability to infiltrate the cancer microenvironment by extravasation or through the help of blood vessels. In this scenario, resident and non-resident elements of the tumor microenvironment constantly interact and together represent a new forming, independent organ within the body (Table 1) (Dvorak et al., 2011). Hence, resident cancer cells produce selected chemokines that will set the composition of the infiltrating, non-resident fraction through the recruitment of leukocytes expressing specific chemokine receptors (reviewed in Toh et al., 2012; Viola et al., 2012). An example of cancer microenvironment composition is depicted in Figure 1 (Mattei et al., 2012), illustrating a section of a B16.F10 melanoma tumor grown in C57Bl/6 syngeneic mice. Hematoxylin/Eosin staining evidences the presence of infiltrating leukocytes surviving the tumor mass (Figure 1A) as well as blood vessels and other structural components inside the tumor milieu (Figure 1B).

Recent studies indicate a role for microRNAs (miRs), pleiotropic regulators of gene expression, as critical components of the tumor microenvironment. Deregulation of miR expression at the tumor site has been reported to affect tumor progression and metastasis (Li et al., 2013). It has been evidenced that cancer cells are endowed with the ability to produce some classes of miRs, such as miR21 and miR29a (Fabbri, 2012; Fabbri et al., 2012). When produced by cancer cells, these little, non-coding, sequences of RNA were internalized by exosomes and secreted...
Table 1 | Main structural and cellular components of the tumor microenvironment.

| Macrostructure | Subcomponents                                                                 |
|----------------|-----------------------------------------------------------------------------|
| RESIDENT       | Blood vessels Endothelial cells Pericytes Mesenchymal stem cells Mesenchymal cancer cells Fibroblasts Cancer-associated fibroblasts Cancer stem cells |
|                | Structural components Adhesion molecules Cytokines Chemokines                |
| NON-RESIDENT   | Infiltrating leukocytes T lymphocytes B lymphocytes Monocytes Dendritic cells Macrophages Myeloid suppressor cells Natural killer cells Circulating stem cells |
| Tumor-derived cells | Metastatic cancer cells Cancer stem cells                                    |

outside the cell, diffusing in the tumor milieu. By exploiting their expression of TLRs, such as TLR-7 (in mice) and TLR-8 (in humans), neighboring immune cells promptly captured these RNA sequences and internalized them via the exosomes. At this point, miR21 and miR29a exert their action by altering the transcriptional machinery of the cells (Fabbri, 2012; Fabbri et al., 2012). Of note, all immune cells expressing TLRs, such as DCs, are potentially exposed to this scenario. Therefore, miRs can be seen as integrated components of the tumor bed, acting as paracrine biological factors that contribute to the crosstalk between cancer and immune cells, together with the cytokine network generated therein, and orchestrating the fate of cancer progression.

**IMMUNE CELLS INFILTRATING THE TUMOR MICROENVIRONMENT: ROLE IN CANCER PROGRESSION**

Immune cell infiltration within a solid tumor is a naturally occurring event, when cells belonging to immune system enter within the tumor microenvironment by means of tumor-forming blood vessels and/or extravasation. This event can sometimes lead to blocking of cancer progression and thus limit or even prevent the generation of metastasis (Vesely et al., 2011). In general, this occurs when tumor progression is at early stages as a result of host immunosurveillance. At this point, if the organism is able to generate a prompt tumor-specific immune response, cancer progression is contrasted by immune forces and sometimes inhibited. In many cases, unfortunately, the host is unable to generate an effector immune response toward the tumor, due to the ability of the tumor to activate immunosuppressive mechanisms that circumvent or dampen immunity forces, thus leading to tumor escape from host immunosurveillance. In this scenario, the balance of immune populations endowed with effector vs. suppressive activities at the tumor site, is a critical parameter predicting cancer progression.

**MACROPHAGES**

Macrophages represent a significant portion of the tumor mass, and they certainly operate as fundamental actors in various types of solid cancers (Hao et al., 2012). These cells are generated from blood monocytes, which differentiate into two distinct macrophage types, schematically identified as M1 (or classically activated) and M2 (or alternatively activated) (Hao et al., 2012). In presence of LPS/IFN-γ, monocytes differentiate in the...
M1-polarized macrophages, characterized by the production of high levels of IL-1, IL-10, IL-23, TNF-alpha as well as CXCL10. Instead, M2-polarized cells are generated when monocytes differentiate in presence of IL-4, IL-10, and IL-13 (Martinez et al., 2009; Pollard, 2009). M1- and M2-polarized macrophages are endowed with opposite functional roles in terms of tumor suppression and immune stimulation. Indeed, whereas M1 cells, by virtue of their ability to elicit Myd88/TLR pathways, enhance immune responses and restrain tumor progression, M2 macrophages switch-off the immune system and promote tumor development (Solinas et al., 2009). Moreover, human renal cell carcinoma has been reported to be frequently infiltrated with M2 tumor-associated macrophages (TAMs) promoting cancer progression. These TAMs produce high levels of IL-10 and CCL2, and display an elevated expression of 15-lipoxygenase-2 (15-LOX2) enzyme. Together, these factors allow infiltrating TAMs to promote inflammation, immunosuppression, and malignant progression of renal cancer carcinoma (Daurkin et al., 2011; Eruslanov et al., 2011). Furthermore, melanoma-infiltrating macrophages produce significant amount of adrenomedullin, which acts in an autocrine manner to promote their polarization toward the M2 phenotype. The generation of M2 macrophages enforce malignant progression and suppresses Cytotoxic T lymphocytes (CTL) activity as well as angiogenesis (Chen et al., 2011). Likewise, M2 macrophages were shown to play a crucial role in colon cancer progression. In a mouse model of colorectal cancer, TAMs were shown to play an indirect role by eliciting the recruitment of CCR6+ T REG lymphocytes inside the tumor mass, which then promote neoplastic progression by stimulating the secretion of CCL20 (Liu et al., 2011). In addition to sustaining tumor progression, M2 macrophages also promote angiogenesis. In this regard, mature F4/80+ CD68+ alternatively activated M2 macrophages were shown to be endowed with a strong CTL-suppressive activity in a murine B16-F10 T cell lymphoma model (Van Ginderachter et al., 2006; Chen et al., 2011).

**T LYMPHOCYTES**

Both preclinical and clinical studies suggest a strict correlation between the presence of tumor-infiltrating lymphocytes (TILs) with a favorable prognosis in a wide number of solid tumors (Galon et al., 2006; Fridman et al., 2012; Senovilla et al., 2012), although not all lymphocyte types are endowed with anti-tumor activity (Vesely et al., 2011). CTL play a relevant role in the process of tumor rejection. They are defined as CD8+ T cells producing massive amounts of IFN-γ and compounds necessary for their cytotoxic activity, such as granzyme B and perforin. The key role of CTL both in immunosurveillance against rising malignancies and in contrasting the metastatic expansion has been demonstrated in mouse models exploiting UV-induced skin cancers (Ward et al., 1990), chemically induced papilloma (Yusuf et al., 2008), and in the ret oncogene transgenic model of spontaneous melanoma (Eyles et al., 2010). High frequencies of circulating CD8+ T lymphocytes were detected in patients with metastatic melanoma, specific for Melan-A/MART-1, MAGE-10, and Ny-Eso-1, and CTL have also been found infiltrating melanoma metastases (Clark et al., 1989; Clemente et al., 1996; van Houw et al., 2008; Fuertes et al., 2011). On this basis, adoptive transfer of CTL is therapeutically effective for mouse tumor models, although to a minor extent for cancer patients (Mempel and Bauer, 2009). These T cells, attracted by chemotactic stimuli secreted by the tumor mass, acquire the ability to migrate toward it. CTL do not require integrin to interact with neoplastic cells and are endowed with the ability to shift between components of tumor mass by means of ameboid locomotion (Weigelin et al., 2011). Time-lapse microscopy in a mouse melanoma model illustrated that melanoma-specific CTL effectively traffic to the melanoma site, where they engage contact with the B16.F10 cells via TCR/MHC-peptide interactions (Weigelin et al., 2011). Subsequently, tumor cells undergo apoptotic cell death induced by cytotoxic activity of CTL. These forming apoptotic bodies are made available for tumor-infiltrating dendritic cells (DC) that are thus allowed to sustain the systemic tumor-specific immunosurveillance by migrating to tumor-draining lymph nodes and other distant lymphoid organs, such as spleen, in order to present the processed peptides to naïve T cells. Moreover, it is also widely documented that the presence of TILs, including CTLs, is correlated with a favorable prognosis for several types of cancers, such as colon, breast, lung, ovarian, and esophageal cancer, just to cite a few (Naito et al., 1998; Schumacher et al., 2001; Zhang et al., 2003; Sato et al., 2005; Alexe et al., 2007; Al-Shibli et al., 2008; Fridman et al., 2012). The killing efficiency of target tumor cells by CTL is dependent on several factors, such as the cytokine/chemokine patterns produced by the tumor microenvironment, the molecular plasticity of tumor cells to evade CTL-induced killing and the strength of TCR/MHC-peptide interactions. In this regard, melanoma cells have been shown to down-regulate the MHC-I surface expression, thus bypassing the interaction with CTL via TCR (Mempel and Bauer, 2009). Of note, some reports demonstrated that induction of co-stimulatory molecule expression in human melanoma cell surface led to stimulation of CTL activity by Natural killer (NK) cells (Tarazona et al., 2004).

A significant fraction of TILs is composed by the regulatory T (T REG) cells, endowed with potent suppressive activity that counteract anti-tumor effector responses and favor tumor escape and progression. T REG cells were reported to infiltrate a wide range of mouse and human tumors, such as melanoma, lung adenocarcinoma, breast cancer, and gastrointestinal tumors (Quezada et al., 2011; Wang et al., 2012b). Elevated frequencies of T REG cells in peripheral blood and at the tumor site of cancer patients correlate with poor prognosis and reduced survival. However the mechanisms driving T REG cell expansion, accumulation, and migration to the tumor site are currently unknown. It is likely, that factors relevant within the tumor microenvironment, such as the presence of TGF-β and low antigen stimulation, may play a role in the induction of T REG cells in vivo (Quezada et al., 2011). Through the secretion of inhibitory cytokines and the expression of surface markers, T REG cells inhibit the effector function of most immune cells, including T and B cells, DC, macrophages, and NK cells (Wang et al., 2012b). FoxP3+ T REG cells within tumor burden express elevated levels of multiple suppressive receptors such as PD-1, CTLA-4, TIM-3, LAG-3, and GITR (Sakuishi et al., 2010; Park et al., 2012b). The identification of these receptors has gained interest for the development of targeted anti-tumor strategies aimed at selectively depleting T REG cells at the tumor site.
Similar encouraging results have been obtained with melanoma to reduce the frequencies of T<sup>REG</sup> cells and to increase the numbers of effector TILs in mice bearing established B16.F10 melanoma, improving the efficacy of tumor vaccines (Curran et al., 2010). Similar encouraging results have been obtained with melanoma patients, suggesting that approaches aimed at combining T<sup>REG</sup> cell depletion-based immunotherapy with current tumor treatment protocols may be promising strategies in clinical oncology (Hodi et al., 2010). However, since PD-1 and CTLA-4 are not uniquely expressed by T<sup>REG</sup> cells, these results may be attributable to the blockade or re-activation of other T cell subsets (Badoval et al., 2013). In some cases T<sup>REG</sup> cells may also contrast tumor progression. Indeed, T<sup>REG</sup> lymphocyte infiltration has been associated with favorable prognosis in several types of solid cancers, such as ovarian, bladder, head/neck, and colorectal tumors (Badoval et al., 2009; Fridman et al., 2012). The mechanisms by which T<sup>REG</sup> cells exert opposite function, depending on the tumor type, are still under investigation, although it is plausible to hypothesize that the phenotypical uniqueness of each cancer microenvironment may elicit the recruitment of different T<sup>REG</sup> cell subsets (Fridman et al., 2012).

**DENDRITIC CELLS**

The involvement of DC in neoplastic progression became increasingly evident in the past 10 years, and has been shown by different research groups (Preynat-Seauve et al., 2006; Shurin et al., 2006; Fuertes et al., 2011; Galluzzi et al., 2012). Indeed, DC have been shown to infiltrate different types of primary solid tumors. The crucial role of these cells in the process of cancer progression is dictated by their unique property of potential antigen presenting cells (APC) capable to prime naïve T lymphocytes. Several investigations indicate that DC can be endowed with capability to yield an active tumor-specific immune response that ultimately reflects in tumor rejection (Preynat-Seauve et al., 2006). It has been demonstrated that DC present tumor-specific peptides to activated T lymphocytes during melanoma progression in tumor-draining lymph nodes (Fuertes et al., 2011; Gerlini et al., 2012a,b). On the other hand, the cancer immunosuppressive environment may cause DC to develop functional impairments resulting in failure to activate T cells. (Chaux et al., 1997a,b; Vicari et al., 2002). In this respect, DC may be viewed as a double-edged sword at the tumor site affecting either positively or negatively the anti-tumor response, depending on the composition of the tumor microenvironment.

Tumor-infiltrating DC (TIDC) are present in different types of solid cancers, including colon lesions and epitheliomas (Michielsen et al., 2011, 2012), but the largest number of TIDC has been found in melanoma (Furumoto et al., 2004). These TIDC are composed by myeloid and to a lesser extent plasmacytoid DC (Mattei et al., 2012). The latter display an immature phenotype in situ, but retain the ability to mature into fully competent APC following dissociation from the tumor bulk, without the need of cytokine or bacterial product exposure (Preynat-Seauve et al., 2006). In this regard, dying tumor cells are thought to provide maturation signals. Therefore, DC spontaneously infiltrate melanoma and other types of solid cancers, and are potentially endowed with the capability to process a soluble tumor-associated antigen (Preynat-Seauve et al., 2006). These TIDC then migrate toward draining lymph nodes in order to activate both naïve CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocytes (Fuertes et al., 2011; Gerlini et al., 2012a,b). Therefore, newly generated cytotoxic CD8<sup>+</sup> T cells may further contribute to tumor rejection by migrating toward the tumor site. The extent of tumor infiltration by mature DC has been often correlated with favorable prognosis in a wide array of clinical cancers (Cox et al., 2005; Ladanyi et al., 2007; Park et al., 2012c). In a mouse model of melanoma, it was recently shown that host immunodeficiency results in poor tumor infiltration by effector immune cells, such as T cells and DC, and closely associates with melanoma progression (Mattei et al., 2012). In this model, melanoma phenotype was shown to be shaped directly by cells of the immune system through release of soluble factors within the tumor microenvironment (Businaro et al., 2013).

Recent work demonstrated the crucial role of CD8α<sup>+</sup> DC in the natural mechanisms of cancer immunosurveillance through response to endogenous type I IFN and induction of CTL-mediated tumor rejection (Diamond et al., 2011; Fuertes et al., 2011). The importance of CD8α<sup>+</sup> DCs in anticancer response stems in their unique ability to process and present cellular antigens, in a process known as cross-presentation (den Haan et al., 2000; Joffre et al., 2012). Cross-presentation is the ability of APC to process exogenous antigens and present the derived peptides to the MHC-I molecules, rather than conveying them to the classical MHC-II pathway. Cross-presentation allows APCs to present those antigens that are not expressed by the APC itself and is crucial for the generation of CTLs against intracellular pathogens or tumors of non-hematopoietic origin. This occurs through a process named cross-priming and requires optimal stimulation of the cross-presenting DC (referred to as DC licensing) by means of “danger signals,” such as those emitted from damaged cells, or by inflammation (Kurts et al., 2010). In fact, in the absence of an activation stimulus that “licenses” DC, antigen cross-presentation does not result in cross-priming, but rather in cross-tolerance. Of note, type I IFN have been shown to provide strong signal for CD8α<sup>+</sup> DCs promoting CD8<sup>+</sup> T cell cross-priming in vivo against antigens derived from dying tumor cells (Lorenci et al., 2011). However, the extent of a tumor-specific immune response in cancer patients is a rare event. It has been hypothesized that the reasons why a patient fails rather than succeed to give an effective immune response toward the tumor are essentially three, all strictly related to the composition of the cancer microenvironment: (i) immunosuppressive cytokines such as IL-10, TGF-β, VEGF, or PGE2, interfering with the generation of immunity (Pardoll, 2003), (ii) tumor-secreted chemokines that sequester antigen-loaded DC, thus impeding them to migrate toward lymph nodes (Hirao et al., 2000), (iii) inadequate ability of TIDC to capture tumor antigens, due to poor apoptosis within cancer microenvironment (den Haan et al., 2000). A recent research of Chiba and co-workers evidenced that the transmembrane protein TIM-3 can act as a molecular switch by which TIDC regulate innate immune responses against tumors. Indeed, several tumorogenic and angiogenic factors, such as VEGF and IL-10, released by the tumor in situ induce TIM-3 expression on TIDC surface, resulting in the suppression of innate immune responses to nucleic acids by binding...
to the damage-associated molecular pattern molecule, HMGB1 (Chiba et al., 2012; Mattei and Schiavoni, 2013). These findings have revealed a novel strategy of tumor escape from host innate responses to nucleic acids involving TIDC and provided important insights for therapy design involving TIM-3 targeting.

Some interesting findings suggest that tumor-specific immune responses can also occur in certain structures distinct from secondary lymphoid organs, the so-called Tertiary Lymphoid Structures. Originally discovered for their importance in autoimmune diseases (Takemura et al., 2001), these singular structures have subsequently been identified in human lung cancers (Dieu-Noéjean et al., 2008) and more recently in melanoma metastases (Cipponi et al., 2012). Tertiary Lymphoid Structures exhibit a well-defined organization, with mature DC and T cells adjacent to B cell follicles, thus suggesting that these structures may be a site where tumor-specific T cell activation occurs (Fridman et al., 2012).

**NATURAL KILLER CELLS**

Natural killer cells are large granular lymphocytes acting by their cytotoxic capacity and massive cytokine production. NK cells share with macrophages the surface expression of CD16 (FcyRIII), but are diversified from them by expression of CD7, CD56, and CD57 (Milush et al., 2009; Yasuda et al., 2011; Senovilla et al., 2012) and by mechanisms of pathogen killing. Indeed, whereas macrophages kill target cells by phagocytosis, NK cells mediate target cell lysis by secretion of perforin- and granzyme B-containing granules (Pardo et al., 2009; Afonina et al., 2010). A recent report demonstrated that NK cells are endowed with a potent ability to secrete calcium ions, and that this function allow these cells to increase their killing ability (Schwarz et al., 2012). For their killing activity, NK cells cover an important role in immune responses against tumors. Another interesting function of NK cells is the so-called “DC editing.” This term specifies the ability of activated NK cells to interact with autologous DC and kill those cells that are not fully mature. Through this process, NK cells contribute to maintain the reservoir of immunogenic DC by killing potentially tolerogenic DC thus optimizing effector anti-tumor responses (Moretta, 2002; Moretta et al., 2006; Morandi et al., 2012).

The functionality of NK cells is fundamental for contrasting the growth and metastatic process of several types of cancers. For example, several reports have elucidated the role of NK cells in killing cancer cells in murine models of melanoma, colon cancer, lung cancer, and breast cancer (Azogui et al., 1991; Pham-Nguyen et al., 1999; Velthuis et al., 2003; Carrega et al., 2009; Frings et al., 2011; Kim et al., 2011; Takeda et al., 2011; Vesely et al., 2011; Roberti et al., 2012a; Srivastava et al., 2012). There are several NK receptors, such as DNAM-1, CD155, CD16, CD69, NKP30, and NKP46, whose surface expression is fundamental for maintaining cancer immunosurveillance (Clausen et al., 2003; García-Iglesias et al., 2009; Lakshmikanth et al., 2009; Chan et al., 2010; Levy et al., 2011; Pfeiffer et al., 2011; Gleason et al., 2012; Park et al., 2012a). In this regard, some research groups investigated the intratumoral phenotypic profile and functions of NK cells in primary human tumors of non-small cell lung carcinoma (NSCLC) by using the NK cell marker NKP46. The data showed that intratumoral NK cells from these patients display a deeply altered phenotype that strongly contributed to the NSCLC progression in these patients (Platonova et al., 2011). These results strengthen the key role of the cancer microenvironment and its composition, and identify NK cells as important predictive biomarkers of neoplastic disease progression. A recent study utilizing mouse tumor models elucidated the importance of NK cells in a vaccination strategy against lung cancer. A survivin-based vaccination, coupled to the use of novel form of the 4-1BB co-stimulatory molecule as an adjuvant has been effective in completely suppressing 3LL lung carcinoma progression. The vaccine efficacy was correlated with potent killing responses of NK cells (Srivastava et al., 2012). Another report highlighted the role of NK cells resident in lung tissue during the generation of lung metastases. These findings have elucidated that IFN-γ production by these lung-resident NK cells markedly repressed the formation of metastases in an experimental mouse melanoma model (Takeda et al., 2011).

Defects in NK cell number or phenotype are events that dictate the fate of neoplastic diseases other than lung carcinoma. Several investigations defined the key role of NK cell receptors in melanoma. This is the case of DNAM-1 that interacts with the CD155 NK-specific receptor and promote the killing of melanoma metastasis and the generation of a “cytokine storm” that contributes to the killing activity (Chan et al., 2010). Many studies reported possible mechanisms by which melanoma cells escape killing activity of NK cells (Balsamo et al., 2012; Pietra et al., 2012; Wang et al., 2012a). Nevertheless, strategies aimed at promoting and sustain the melanoma-specific killing activity of NK cells are only at early stages or poorly effective. A recent report showed an active role of the chemotherapeutic drug dacarbazine, largely used for this type of neoplastic disease, in activating the expression of NK1G receptor on NK cell surface, thus restoring the killing activity of NK cells toward melanoma cells (Hervieu et al., 2012). Similar encouraging approaches have been recently started for breast cancer by using the chemotherapeutic agent Cetuximab. This drug was shown to be effective in promoting NK cell killing activity in high relapse rate, triple negative breast cancer patients. Indeed, Cetuximab restored IL-2/IL-15-mediated NK cell killing activity, thus markedly improving the outcome of these patients (Robert et al., 2012b). Taken together, these data strongly support a key role of NK cells in tumor progression. Indeed, when activated, NK cells fight malignant cells inside the microenvironment by direct killing as well as by contrasting the generation of metastatic foci.

**MYELOID-DERIVED SUPPRESSOR CELLS**

Cancer patients and tumor-bearing experimental mice undergo dramatic changes in their hematopoietic progeny. These modifications are mainly due to accumulation of myeloid cells, including myeloid-derived suppressor cells (MDSC) (Serafini et al., 2004). These cells represent a heterogeneous population, either of monocytic or granulocytic origin, generated by and released from the bone marrow in response to a wide array of stimuli (Solito et al., 2011). MDSC are characterized by the surface expression of CD11b and Gr-1 markers, and their common functional feature is the repression of the effector functions of T lymphocytes and NK cells (Serafini et al., 2004; Gabrilovich and Nagaraj, 2009). For their potential to compromise both innate and adaptive immunity, tumor-infiltrating MDSC critically control cancer progression.
By using STAT6−/− mice models transplanted with 4T1 cancer cells, Sinha et al. (2005) showed that MDSC render 4T1 mammary tumors poorly immunogenic by suppressing the activation of CD4+ and CD8+ T cells. The involvement of STAT signaling in the immunosuppressive activity of MDSC in cancer has been further evidenced in studies on human head and neck squamous cell carcinoma and breast cancer, suggesting a pivotal role of STAT3 and STAT1 pathways, respectively, for MDSC suppressive activity within cancer microenvironment (Hix et al., 2013; Vasquez-Dunddel et al., 2013). Other independent investigations demonstrated that mice injected with 4T1 cells and subsequently treated with cyclophosphamide displayed tumor progression and metastatic spread despite drug treatment. Strikingly, the microenvironment of these tumor-bearing mice displayed a very high number of infiltrating MDSC, and this explained the unwanted inefficacy of chemotherapeutic cure. In addition, CD4+ and CD8+ T infiltrating cells have been shown to promote and sustain this effect by releasing IFN-γ (Guo et al., 2012b). Because the main property of MDSC is to contrast the immunosurveillance mechanisms of CD8+ and CD4+ T lymphocytes, the balance between T cells and MDSC within the cancer microenvironment may be a crucial cornerstone in dictating the fate of the neoplastic disease. Another recent report employing transgenic mouse models evidences that NK cells can potentially render T cells resistant to the suppressor activity of MDSC, and this markedly contribute to the generation of an effective adoptive transfer therapy with HER-2/neu tumor-reactive T cells and activated non-T cells, including NK cells (Kmieciak et al., 2011). In the mouse model of 4T1 metastatic breast carcinoma, accumulation of CD11b+Gr-1−MDSCs within the tumor tissue has been associated with tumor progression and bone metastasis (Bunt et al., 2007; Danilin et al., 2012) and a recent report showed that MDSC recruitment is triggered by Macrophage Migration Inhibitory Factor, an inflammatory cytokine expressed by the tumor (Simpson et al., 2012). Likewise, marked tumor infiltration and systemic expansion of CD11b+Gr-1+MDSC was found to be associated with enhanced tumor growth and malignant phenotype in an immunocompromised IRF-8−/− mouse model transplanted with B16.F10 melanoma (Mattei et al., 2012). Together, these data strongly suggest a close correlation between intratumoral MDSC expansion with tumor progression and metastatic process.

The immunosuppressive functions of MDSC have been studied in several models of neoplastic diseases. It appears that MDSC may mediate T cell suppression through cell-cell contact or, alternatively, through release of soluble mediators, such as nitric oxide, arginase-1, reactive oxygen species or suppressive cytokines (e.g., IL-10) (Gabrilovich et al., 2012; Kerkar and Restifo, 2012). Studies on B16.F10 tumor-bearing mice have demonstrated that CCL5, a chemokine largely produced by MDSC (Zhang et al., 2012), is required for intratumoral recruitment of TREG cells and melanoma expansion (Schlecker et al., 2012). Moreover, MDSCs have been shown to skew the differentiation of CD4+ T cells into TREG (Huang et al., 2006), to induce an M2 phenotype in macrophages and to impair DC function, suggesting the existence of multiple overlapping regulatory mechanisms that dampen anti-tumor effector responses (Gabrilovich et al., 2012). Finally, MDSC facilitate tumor growth by producing pro-angiogenic factors, such as VEGF-A (Finke et al., 2011). Overall, MDSC exert pro-tumorigenic activity both through direct mechanisms and by employing a myriad of immunosuppressive mechanisms at the tumor site that blunt effector T cell responses.

**OTHER TUMOR-INfiltrATING IMMUNE CELL SUBSETS: γδ T AND NKT CELLS**

Besides the traditional players of anti-tumor immunity, emerging evidences suggest that other subsets of immune cells infiltrate solid tumors and may also contribute in cancer growth control. Among these, γδ T cells represent a small part of the lymphocyte population that share, with all T cells, the surface expression of TCR. Unlike αβ T cells, γδ T lymphocytes express a TCR complex where CD3 is associated to a γ and δ chains (Wu et al., 1988). These lymphocytes were originally characterized as strong cytotoxic and IFN-γ-producing cells, thus making them prototypic anti-tumor mediators. Indeed, γδ T lymphocytes have been linked to cancer progression since the early 1990s, when an encouraging study demonstrated their infiltration in human skin tumors, even though no clear indications about their function was given (Miescher et al., 1990). About a decade later, by employing mice lacking γδ T cells, Girardi et al. (2001, 2003) observed that these mice were highly exposed to carcinogen-induced cutaneous tumors, thus directly demonstrating the protective role of these cells in skin tumors. In the murine B16 melanoma model, γδ T cells were shown to infiltrate tumor lesions soon after transplantation and to provide an early source of IFN-γ (Gao et al., 2003). Other recent examples demonstrating a protective role of γδ T cells have been provided by two significant reports suggesting the presence of γδ T lymphocytes as a favorable prognostic factor for human breast cancer and melanoma (Kabelitz et al., 2007; Cordova et al., 2012; Ma et al., 2012). On the other hand, studies in mouse tumor models have demonstrated that γδ T cells within the tumor microenvironment exert an inhibitory action on CTL and NK cytolytic activity through production of IL-10 and TGF-β, resulting in the induction of tumor-specific immune tolerance (Seo et al., 1999; Ke et al., 2003). Recently, by employing IL-17−/− mice two independent groups reported a subset of IL-17-producing γδ T cells infiltrating murine tumors, although opposite results were obtained regarding the anti-tumor activity of these cells. Wakita et al. (2010) showed that IL-17 produced by tumor-infiltrating γδ T cells promotes tumor progression by inducing angiogenesis in mouse models of methylcholanthrene-induced transplantable fibrosarcoma, skin, and colon carcinoma. In contrast, Zitvogel’s group showed in several subcutaneous tumor lines that early cancer infiltration by IL-17-producing γδ T cells is required for optimal tumor colonization of IFN-γ-producing CD8+ T cells and therapeutic efficacy of anticancer chemotherapy, in a mechanism requiring IL-1R1 and IL-1β, thus implying a beneficial role of IL-17-producing γδ T cells in anti-tumor defense (Ma et al., 2011; Mattarollo et al., 2011). Thus, the role of tumor-infiltrating γδ T cells in cancer immunosurveillance is still controversial and a more detailed characterization of γδ T cells is necessary in a wider set of preclinical tumor models that takes into account the phenotype of functional γδ T cell subsets.
NKT cells have also been reported to infiltrate solid tumors. Initially identified in 1981 by Minato et al. (1981) as a population expressing both a TCR and NK cell markers, NKT lymphocytes are currently known as a subset of innate-like T cell that recognizes Ag presented by CD1d (Kawano et al., 1997; Godfrey et al., 2004; Van Kaer, 2007). The best known subset of CD1d-restricted NKT cells, referred to as type I or invariant NKT (iNKT) cells, is characterized by surface expression of defined variants of α and β chain of the TCR, such as those encoded by vα24, vα14, vβ11, and Jα281 gene segments (Cui et al., 1997; Kawano et al., 1997; Kronenberg, 2005). These cells are conserved between humans and mice and are implicated in many immunological processes, such as production of massive amounts of several cytokines, both pro-inflammatory (i.e., IL-2, IL-17, IFN-γ, and TNF-α) and regulatory (i.e., IL-4, IL-10, and IL-13), which reflect their capacity to differently regulate anti-tumor responses (Swann et al., 2004; Bendelac et al., 2007; Exley et al., 2011). Pioneering work by Cui et al. (1997) showed that mice deficient for vα14+ iNKT cells were unable to mediate IL-12-induced rejection of tumors and that lack of infiltration of vα14 iNKT cell in melanoma tissue resulted in cancer progression and metastatic expansion. Subsequently, it was shown that the defective tumor immunity observed in Jα18+ mice, selectively deficient for iNKT cells, against methylchloranthrene-induced sarcomas and melanoma lung metastasis could be restored by adoptive transfer of IFN-γ-producing iNKT cells from WT donor mice (Crowe et al., 2005). iNKT cells can be recruited to the tumor by inducing local expression of chemokines, such as CCL21 or CXCL16 (Turnquist et al., 2007; Kee et al., 2013), and be functionally activated by the alpha-galactosylceramide producing beneficial effects in a variety of solid tumors (Nakagawa et al., 2000; Osada et al., 2004; Nagato et al., 2012). iNKT cell infiltration in primary tumors has been correlated with a favorable outcome in patients with colorectal carcinoma (Tachibana et al., 2005), neuroblastoma (Metelitsa et al., 2004), and hepatocellular carcinoma (Guo et al., 2012a). On the other hand, iNKT cells have also been described to suppress tumor immunosurveillance based on their production of Th2 cytokines (Terabe et al., 2000; Exley et al., 2011). It has been proposed that the instauration of a protective or suppressive antitumoral activity of iNKT cells may depend on the cytokine pattern of the cancer microenvironment and on the action of suppressive populations, such as MDSC and TAMs (Smyth and Godfrey, 2006; Terabe et al., 2003; Liu et al., 2012). Other, less characterized, CD1d-reactive NKT cells that have non-V24 (V14) invariant or variable TCR (type II NKT) as well as some non-CD1d-reactive NKT cell subsets that share with the NK cells the surface expression of a number of NK-associated receptors, such as CD161 (NK1.1), CD16, and CD56, have been described (Godfrey et al., 2004; Bendelac et al., 2007; Metelitsa, 2011). Several reports have demonstrated that type II NKT cells can modulate suppression of tumor immunosurveillance in multiple tumor models by counteracting iNKT cell activities (Terabe et al., 2005; Berzofsky and Terabe, 2008; Izhak et al., 2013). However, these type II NKT cells have not been characterized in tumor infiltrates yet, indicating the need of further exploration for possible relevance of these cells in the local control of tumor growth and metastatic process.
FIGURE 2 | Role of the cancer stem cells in the development of the tumor microenvironment.

Cancer progression is generated and sustained by several factors, such as epigenetic forces, somatic mutations, and EMT. On the other hand, these events lead to the generation of distinct cancer stem cell clones inside the cancer moiety, and enrich the cancer stem cell niche. During the late stages of tumor progression these stem cell clones sustain the cancer expansion with their self-renewal ability. Thus, the cancer stem cell niche can also be regarded as a reservoir of self-sustaining cells for the tumor microenvironment.

CSC, could affect the angiogenesis and VEGF-A level at the tumor site, especially when its microenvironment is hypoxic. This elicits vascularization extent and thus facilitates angiogenesis itself, which in turn allow CSC proliferation and maintenance inside the cancer microenvironment (Facciabene et al., 2011; Yu et al., 2012).

Effector T lymphocytes exert opposite effects to those observed with TREG cells by induction of CTL capable to repress the expansion of CSC in ovarian cancer. This effect has been exploited to direct CTL to effectively killing ovarian CSC (OCSC) in a chemotherapeutic context. In this report, cell chimeras generated by fusion of DC and OCSC to specifically target the OCSC subpopulations were shown to activate T cells to express elevated levels of IFN-γ with potent killing activity of CD44+ OVCA cells (Weng et al., 2011). The NK have also been reported to affect CSC activities. It has been demonstrated that NK cells are endowed with the ability to kill human melanoma stem cells with high levels of the CD133 marker (Pietra et al., 2009). In this study, the authors were able to show that CD133-positive melanoma CSC, isolated from a FO-1 melanoma cell line by cell enrichment, were effectively killed by activated NK cells. Moreover, myeloid-derived cells such as DC may be effective in targeting Glioma stem cells (GSC), leading to the complete eradication of this malignant primary brain tumor (Ji et al., 2013). Here, the authors prepared a tumor vaccine by loading DC with U251 human GSC lysates and showed that these antigen-loaded DC are endowed with the ability to induce tumor-specific CTLs that killed glioma cells in vitro. TAM have also been shown to modulate the tumorigenic and angiogenic potential of CSC within tumor transplanted mouse model (Jinushi et al., 2011). A recent study reported that inhibition of TAM by targeting either the myeloid cell receptors CSF1R or CCR2 decreases the number of tumor initiating cells in pancreatic tumors (Mitchem et al., 2012). Thus, inhibiting macrophages function can lead to cancer eradication via diminishing the presence of CSC inside the tumor microenvironment. Finally, little is known about the interactions between MDSC and CSC. However, since MDSC are pivotal for the generation and maintenance of an aggressive cancer microenvironment, it has been recently hypothesized that these cells may also act as a distinct tumor niche whose main function is the maintenance of self-renewal ability of the niche itself, thus functionally resembling to CSC (Ye et al., 2010).

Overall, CSC are an important and integrated component of the cancer microenvironment. Through their self-renewal ability, CSC also function by tightly interacting with the other resident and non-resident component of the environment, thus crucially controlling cancer progression and maintaining the tumor mass.
Table 2 | Immune cells infiltrating the tumor microenvironment and their role in tumor progression.

| Cell type                  | Representative infiltrating population | Outcome | Main features of infiltrating cells inside the tumor microenvironment |
|----------------------------|---------------------------------------|---------|---------------------------------------------------------------|
| Macrophages               | M1                                    | TR      | Activation of immune responses by MyDD88/TLR pathways        |
|                           | M2                                    | TP      | Promotion of angiogenesis; suppression of CTL function;     |
|                           |                                       |         | recruitment of CCR6+TREG, positive modulation of the         |
|                           |                                       |         | tumorigenic and angiogenic potential of CSC                  |
| T lymphocytes             | CTL                                    | TR      | Specific tumor cell killing activity                         |
|                           | TREG                                  | TP/TP   | TP: functional suppression of CTL, DC, NK cells, and         |
|                           |                                       |         | macrophages. TR: correlation with good prognosis in some     |
|                           |                                       |         | solid tumors, hypothetically due to lacking of suppressor    |
|                           |                                       |         | activity and other unidentified activities                   |
|                          | γδ T cells                            | TP/TP   | TP: inhibition of CTL and NK cell activity; promotion of     |
|                           |                                       |         | angiogenesis TR: cytotoxic activity, IFN-γ production       |
| Dendritic cells           | CD8α+ DC                              | TR      | Processing and presentation of soluble tumor-associated       |
|                           | Plasmacytoid DC                       | TR      | antigens; Type I IFN-dependent CD8+ T cell cross-priming     |
|                           | TIM-3+ DC                             | TP      | against antigens released from dying tumor cells            |
| NK cells                  | Nkp46+                                 | TR      | Specific tumor cell killing activity by secretion of perforin|
|                           | Nkp30+                                 |         | and granzyme B-containing granules as well as release of    |
|                           | DNAM-1+                               |         | calcium ions; DC editing; killing activity against CSC      |
|                           | CD69+                                 |         |                                                              |
|                           | CD155+                                |         |                                                              |
| NKT cells                 | NK receptors                           | TP/TP   | TP: CD1d-restricted cytotoxic activity; IFN-γ production; APC|
|                           | TCR-α chain variants                  |         | stimulation TR: Th2 cytokine production                      |
|                           | CD1d-restricted                       |         |                                                              |
|                           | CD57+                                 |         |                                                              |
| Myeloid-derived suppressor cells | CD11b+Gr-1+                          | TP      | Repression of the effector function of T lymphocytes and NK  |
| Cancer stem cells         | CD34+ CD133+                          | TP      | cells; highly present in late stages of tumor progression;  |
|                           |                                       |         | promotion of TREG functions; promotion and sustainment of   |
|                           |                                       |         | angiogenesis; present in elevated number in highly aggres-   |
|                           |                                       |         | sive microenvironments                                       |

TP: tumor progression; TR, tumor regression.

NEW APPROACHES TO STUDY THE CANCER MICROENVIRONMENT

Exploiting complex experimental systems such as confocal microscopy, electron microscopy or two photon microscopy allow oncoimmunologists to "capture" suggestive images finely representing the cell–cell interactions occurring in biological systems. However, the existent traditional experimental protocols do not allow monitoring and visualizing in real time the interactions between immune and tumor cells occurring inside the cancer microenvironment.

Over the past decade, innovative approaches devoted to the reproduction of biological systems at the microscale, such as microfluidic platforms, have gained interest for the study of one or multiple biological systems. The first pioneering studies on biosensors performed in 1990s to investigate on the kinetics between the antigen-antibody interactions gave a decisive boost on this research area (Karlsson et al., 1991). This subsequently led to the engineering of microfluidic systems to investigate on biological fluids (Wilding et al., 1994) and, subsequently, on cell systems (Li and Harrison, 1997). Since 2004 microfluidic approaches have
been employed to investigate on cells belonging to immune system to investigate migratory and morphological parameters in response to external stimuli (Lin et al., 2004; Wong et al., 2008; Butler et al., 2010; Li et al., 2011). In addition, a magnetic microfluidic chip has been developed to isolate circulating human colon cancer cells (Choi et al., 2010; Xia et al., 2011) or to study chemotractant properties of tumor cells (George et al., 2007). Other studies have exploited cell-on-chip based platforms to investigate the susceptibility of tumor cells to chemotherapeutic drugs (Liu et al., 2007; Siyan et al., 2009; Kim et al., 2012). Thus, the extreme versatility and the high customization potential of microfluidic-based technologies have open promising perspectives on the use of these approaches for cancer biology studies (Wlodkowic and Cooper, 2010; Wlodkowic and Darzykiewicz, 2010).

In this context, the reconstitution-on-chip of the cancer microenvironment may allow to elucidate the fine mechanisms that mechanically regulate the interactions of tumor cells with other resident and non-resident components, such as the immune cells, as well as the mechanisms driving the differentiation and metastatic mobilization. Recently, a simple cell-on-chip approach has been developed to investigate the crosstalk between two complex biological systems, such as immune system and cancer (Businaro et al., 2013). By using a microfluidic platform consisting of three wide, parallel chambers interconnected via an array of short and narrow capillary migration channels, Businaro and Colleagues were able to visualize and follow, “under the microscope,” the interactions between the immune and cancer cells. The goal of the study was to investigate the role of IRF-8 immune deficiency on immune response to melanoma. Thus, splenic immune cells from IRF-8−/− mice or WT controls were allowed to interact with B16.F10 melanoma cells into the microfluidic structure. The results evidenced a marked inability of IRF-8−/− immune cells to migrate toward and interact with melanoma cells with respect to WT cells. In turn, melanoma cells acquired a more invasive behavior in the presence of immunodeficient cells, indicating a crosstalk between cancer and immune cells shaping the phenotype of tumor cells. Notably, these results are fully compatible with the findings reported in vivo by the same group, suggesting the reliability of the system (Mattie et al., 2012). The observations reported in this study are difficult to obtain with the standard well plate culture experiments, but are easily available with the use of a microfluidic platform. Thus, customized microfluidic platform may be potentially helpful to study, follow, and mimic the plethora of events occurring inside the cancer microenvironment. In addition they can also be utilized as helpful tools in preclinical and clinical investigations.

CONCLUDING REMARKS

Immune cell infiltration within the tumor microenvironment is a crucial requisite for a successful and prompt eradication of the primary tumor itself. Each cell type herein supports the maintenance of the microenvironment itself both functionally and biochemically, by orchestrating cell–cell interactions and secreting a plethora of chemokines and cytokines. This leads to a fine tuning of the timing and modality of immune response, as well as an appropriate modulation and maintenance of angiogenic processes. The final effect of such a strictly related phenomena may either be the generation of a tumor-specific immune response or tumor escape (Table 2).

Thus, a better knowledge of the crosstalk between cancer cells and immune system cells occurring inside the tumor bed is of interest for further improving cancer therapies. In this respect, great benefit for anticancer research and clinical practice may arise from exploiting new versatile biotechnologies, such as microfluidic cell-on-chip platforms.

ACKNOWLEDGMENTS

We thank Dr. Paola Sestili for the helpful technical assistance in preparation of histochemistry sections from tumor-bearing mice. This work was supported by the Italian Association for Research Against Cancer (AIRC) project no. 11610 to Lucia Gabriele and project no. 10720 to Filippo Belardelli.

REFERENCES

Afonina, I. S., Callen, S. P., and Martin, S. J. (2010). Cytotoxic and non-cytotoxic roles of the CTL/NK pro tease granzyme B. Immunol. Rev. 235, 105–116.
Alessi, G., Dalgin, G. S., Scanfeld, D., Tamayo, P., Mesri, J. P., Delis, C., et al. (2007). High expression of lymphocyte-associated genes in node-negative HER2+ breast cancer correlates with lower recurrence rates. Cancer Res. 67, 10669–10676.
Al-Shibli, K. I., Donnem, T., Saad, S., Persson, M., Brennes, R. M., and Buslund, L. T. (2008); Prognostic effect of epithelial and stromal lym phocyte infiltration in non-small cell lung cancer. Clin. Cancer Res. 14, 5220–5227.
Azouz, O., Avriel, M. F., Margulio, A., Guilard, M., Caillou, B., and Prade, M. (1991). Tumor-infiltrating CD3−NK cells are more effective than CD3−+ T cells in killing autologous melanoma cells. J. Invest. Der matol. 97, 425–429.
Badoual, C., Hans, S., Frisdman, W. H., Brasnu, D., Erdman, S., and Tartour, E. (2009). Revisiting the prognostic value of regulatory T cells in patients with cancer. J. Clin. Oncol. 27, e5–e6. author reply e7.
Badoual, C., Hans, S., Merillon, N., Van Ryswick, C., Ravel, P., Benhamouida, N., et al. (2013). PD−1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res. 73, 128–138.
Balsamo, M., Pietra, G., Vermi, W., Moretta, L., Mingari, M. C., and Vitale, M. (2012). Melanoma immunoeediting by NK cells. Oncoimmunology 1, 1607–1609.

Bendelac, A., Savage, P. B., and Teyton, L. (2007). The biology of NKT cells. Annu. Rev. Immunol. 25, 297–336.
Benzulsky, I. A., and Terabe, M. (2008). NKT cells in tumor immunity: opposing subsets define a new immunoregulatory axis. J. Immunol. 180, 3627–3635.
Bonnert, D., and Dick, J. E. (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3, 730–737.
Boral, D., and Nie, D. (2012). Cancer stem cells and niche microenvironments. Front. Biosci. (Elite Ed.) 4, 2502–2514.
Bunt, S. K., Yang, L., Sinha, P., Clements, V. K., Leips, J., and Ostrand-Rosenberg, S. (2007). Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res. 67, 10019–10026.
Bustarano, L., De Ninno, A., Schiavoni, G., Lucarini, V., Ciasca, G., Germanino, A., et al. (2013). Cross talk between cancer and immune cells: exploring complex dynamics in a microfluidic environment. Lab Chip 13, 229–239.
Butler, K. L., Ambravaneswaran, V., Agrawal, N., Bilodeau, M., Toner, M., Tompkins, R. G., et al. (2010). Burn injury reduces neutrophil directional migration speed in microfluidic devices. PLoS ONE 5:e11921. doi:10.1371/journal.pone.0011921
Carrega, P., Pezzino, G., Queirolo, P., Bonaccorsi, I., falco, M., Vita, G., et al. (2009). Susceptibility of human melanoma cells to autologous natural killer (NK) cell
killing: HLA-related effector mechanisms and role of licensed NK cells. PLoS ONE 4:e49132. doi:10.1371/journal.pone.0049132.

Chen, C. J., Andrews, D. M., McGough, N. M., Yagita, H., Gilliland, S., Colonna, M., et al. (2010). DNAM-1/CDC155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases. J. Immunol. 184, 902–911.

Chaux, P., Favre, N., Bonnotte, B., Mouet, M., Martin, M., and Martin, F. (1997b). Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression. A role in the immune tolerance to antigenic tumors. Adv. Exp. Med. Biol. 417, 525–528.

Chaux, P., Favre, N., Martin, M., and Martin, F. (1997b). Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression. Int. J. Cancer 72, 619–624.

Chen, P., Huang, Y., Bong, R., Ding, Y., Song, N., Wang, X., et al. (2011). Tumor-associated macrophages promote angiogenesis and melanoma growth via adrenomedullin in both paracrine and autocrine manners. Clin. Cancer Res. 17, 7230–7239.

Chiba, S., Baghdadi, M., Akiba, H., Yoshiyama, H., Kinoshita, I., Dovnaka-Akita, H., et al. (2012). Tumor-infiltrating DCs suppress nucleic acid-mediated immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat. Immunol. 13, 832–842.

Choi, J. R., Sung, J. H., Shuler, M. L., and Kim, D. (2010). Investigation of portable in situ fluorescence optical detection for microfluidic 3D cell culture assays. Opt. Lett. 35, 1374–1376.

Cipponi, A., Mercier, M., Seremet, T., Baurain, J. F., Theate, I., van den Haan, J. M., Lehar, S. M., and Schiavoni, et al. (2011). The cancer immunoenvironment. J. Natl. Cancer Inst. 103, 468–474.

Eraslanov, E., Daukin, I., Vlieg, J., Daaka, Y., and Kumarswamy, S. (2011). Aberrant PGE metabolism in bladder tumor microenvironment promotes immunosuppressive phenotype of tumor-infiltrating myeloid cells. Int. Immunopharmacol. 11, 848–855.

Exley, M. A., Lynch, L., Varghese, B., Nowak, M., Alatrralchi, N., and Balk, S. P. (2011). Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumor-induced defects. Clin. Immunol. 140, 184–195.

Eyres, J., Paukas, A. L., Wang, X., Toh, B., Prakash, C., Hong, M., et al. (2010). Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J. Clin. Invest. 120, 2030–2039.

Fabbri, M. (2012). TR7s as miRNA receptors. Cancer Res. 72, 6333–6337.

Fabbri, M., Paone, A., Calore, F., Galli, R., Gaudio, E., Santhanam, R., et al. (2012). MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc. Natl. Acad. Sci. U.S.A. 109, 4275–4280.

Danilin, S., Mertel, A. R., Johnson, J. R., Johnson, R. W., Edwards, J. R., and Sterling, J. A. (2012). Myeloid-derived suppressor cells expand during breast cancer progression and promote tumour-induced bone destruction. Oncoimmunology 1, 1484–1499.

Daukin, I., Eraslanov, E., Stoffs, T., Perrin, G. Q., Algoog, C., Gilbert, S. M., et al. (2011). Tumour-associated macrophages mediate immunosuppression in the renal cancer microenvironment by activating the 15-lysoperoxidase-2 pathway. Cancer Res. 71, 6400–6409.

den Haan, J. M., Lehar, S. M., and Bevan, M. J. (2000). CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J. Exp. Med. 192, 1685–1696.

Clemente, G. C., Mihm, M. C. Jr., Bufalino, R., Zarrida, S., Collini, P., and Cascinelli, N. (1996). Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77, 1303–1310.

Cook, V. G., Lebleu, V. S., Keskin, D., Khan, Z., O’Connell, J. T., Teng, Y., et al. (2012). Peri-ecrine depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell 21, 66–81.

Cordova, A., Toia, F., La Mendola, C., Orlando, V., Meraviglia, S., Rinaldi, G., et al. (2012). Characterization of human gammadelta T lymphocytes infiltrating primary malignant melanomas. PLoS ONE 7:e94878. doi:10.1371/journal.pone.0094878.

Cox, N., North, M., Burke, M., Singhal, H., Renton, S., Aqel, N., et al. (2005). Plasmacytoid dendritic cells (PDC) are the major DC subset innately producing cytokines in human lymph nodes. J. Leukoc. Biol. 78, 1142–1152.

Crowe, N. Y., Coquet, J. M., Berzin, S. P., Kyparissoudis, K., Keating, R. S., Colonna, M., et al. (2010). Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumor-induced defects. Clin. Immunol. 140, 184–195.

Eyres, J., Paukas, A. L., Wang, X., Toh, B., Prakash, C., Hong, M., et al. (2010). Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J. Clin. Invest. 120, 2030–2039.

Fabbri, M. (2012). TR7s as miRNA receptors. Cancer Res. 72, 6333–6337.

Fabbri, M., Paone, A., Calore, F., Galli, R., Gaudio, E., Santhanam, R., et al. (2012). MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc. Natl. Acad. Sci. U.S.A. 109, E2110–2116.

Facciabene, A., Peng, X., Hagemann, I., and Merad, M. (2004). Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J. Clin. Invest. 113, 774–783.

Gabrilovich, D. I., and Nagaraj, S. (2009). Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9, 162–174.

Gabrilovich, D. I., Ostrand-Rosenberg, S., and Bronte, V. (2012). Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12, 253–268.

Galluzzi, L., Senovilla, L., Vacchelli, E., Eggermont, A., Fridman, W. H., and Galon, J. (2012). Trial watch: dendritic cell-based interventions for cancer therapy. Oncimmunology 1, 1111–1134.

Galon, J., Costes, A., Sanchez-Cabero, F., Kreilovsky, A., Mlecnik, B., Lagorce-Pages, C., et al. (2006). Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960–1964.

Gao, Y., Yang, W., Pan, M., Scully, E., Girardi, M., Augenlicht, L. H., et al. (2003). Gamma delta T cells provide an early source of interferon gamma in tumor immunity. J. Exp. Med. 198, 433–442.

Garcia-Iglesias, T., Del Toro-Arreola, A., Albarran-Somoza, B., Del Toro-Arreola, S., Sanchez-Hernandez, P. E., Ronquez-Duansas, M. G., et al. (2009). Low NKp30, NKp46 and NK2G2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions. BMC Cancer 9:186. doi:10.1186/1471-2407-9-186
Hao, N. B., Lu, M. H., Fan, Y. H., Gupta, P. B., Chaffer, C. L., and Weinberg, R. A. (2009). Cancer stem cells—the pericytes in the liver. Pflugers Arch. doi:10.1007/s00424-012-1209-5

Herveu, A., Rabe, C., Veyran, F., Chalmin, E., Bruchaud, M., Yahes, P., et al. (2012). Dacarbazine-mediated upregulation of NRG2D ligands on tumor cells activates NK and CD8 T cells and restricts melanoma growth. J. Investig. Dermatol. doi:10.1038/jid.2012.273

Hirao, M., Onai, N., Hiroshi, K., Watkins, S. C., Matushima, K., Robbins, P. D., et al. (2000). CC chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: critical role in migration from the tumor site to draining lymph nodes. Cancer Res. 60, 2209–2217.

Hix, L. M., Karavitis, J., Khan, M. W., Shi, Y. H., Khazaie, K., and Zhang, M. (2013). Tumor STAT3 transcription factor activity enhances breast tumor growth and immune suppression mediated by myeloid-derived suppressor cells. J. Biol. Chem. doi:10.1074/jbc.M112.441402

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haasen, J. B., et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723.

Huang, H., Zhou, R., Fan, H., Han, D., Chen, M., Yan, L., et al. (2006). Generation of monoclonal antibodies and epitope mapping of ApxIV A of Actinobacillus pleuropneumoniae. Mol. Immunol. 43, 2130–2134.

Iwakaki, K., Komaki, M., Yokoyama, N., Tanaka, Y., Taki, A., Kimura, Y., et al. (2012). Periodontal ligament stem cells possess the characteristics of pericytes. J. Periodontal. doi:10.1902/jop.2012.120547

Izaki, L., Ambrosio, E., Kato, S., Parish, S. T., O’Konek, J. K., Weber, H., et al. (2013). Delicate balance among three types of t cells in concurrent regulation of tumor immunity. Cancer Res. 73, 1514–1523.

Ji, B., Chen, Q., Liu, B., Wu, L., Tian, D., Guo, Z., et al. (2013). Glisoma stem cell-targeted dendritic cells as a tumor vaccine against malignant glioma. Tumor Med. J. 54, 92–99.

Jinushi, M., Chiba, S., Yoshihama, H., Masutomi, K., Kinoshita, I., Desakaki-Akita, H., et al. (2011). Tumor-associated macrophages regulate tumorigenicity and antitumor drug responses of cancer stem-initiating cells. Proc. Natl. Acad. Sci. USA 108, 12425–12430.

Joffre, O. P., Segura, E., Savina, A., and Amigorena, S. (2012). Cross-presentation by dendritic cells. Nat. Rev. Immunol. 12, 557–569.

Kabelitz, D., Wesch, D., and He, W. (2007). Perspectives of gammadelta T cells in tumor immunology. Cancer Res. 67, 5–8.

Carlsson, R., Michaelsson, A., and Mattsson, L. (1991). Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. J. Immunol. Methods 145, 229–240.

Kawano, T., Gui, J., Koekuzka, Y., Toura, L., Kaneko, Y., Motoki, K., et al. (1997). CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 278, 1626–1629.

Ke, Y., Kapp, L. M., and Kapp, J. A. (2003). Inhibition of tumor regression by gammadelta T cells and IL-10. Cell. Immunol. 221, 107–114.

Kee, J. Y., Ita, A., Hojo, S., Hashimoto, I., Igarashi, Y., Tsukada, K., et al. (2013). Chemokine CXCL16 suppresses liver metastasis of colorectal cancer via attenuation of tumor-infiltrating natural killer T cells in a murine model. Oncol. Rep. 29, 975–982.

Kerark, S. P., and Restifo, N. P. (2012). Cellular constituents of immune escape within the tumor microenvironment. Cancer Res. 72, 3215–3230.

Kim, H., Kim, S. H., Kim, M. J., Kim, S. J., Park, S. J., Chung, J. S., et al. (2011). EGFR inhibitors enhanced the susceptibility to NK cell-mediated lysis of lung cancer cells. J. Immunother. 34, 372–381.

Kim, I., Taylor, D., Agraval, N., Wang, H., Kim, H., Han, A., et al. (2012). A programmable microfluidic cell array for combinatorial drug screening. Lab Chip 12, 1813–1822.

Kniecicak, M., Basu, D., Payne, K. K., Toor, A., Yacoub, A., Wang, X. Y., et al. (2011). Activated NK cells and NK cells render T cells resistant to myeloid-derived suppressor cells and result in an effective adoptive cellular therapy against breast cancer in the FVB/N202 transgenic mouse. J. Immunol. 187, 708–717.

Kronenberg, M. (2005). Toward an understanding of VISTA biology: progress and paradoxes. Annu. Rev. Immunol. 23, 877–900.

Kurts, C., Robinson, B. W., and Knolle, P. A. (2010). Cross-presentation in health and disease. Nat. Rev. Immunol. 10, 403–414.

Ladanyi, A., Kiss, J., Somlai, B., Gilde, K., Fejos, Z., Mohos, A., et al. (2007). Density of DC-LAMP(+) macrophage and dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol. Immunother. 56, 1459–1469.

Lakshmikanth, T., Burke, S., Ali, T. H., Kimpfier, S., Ursini, F., Ruggeri, L., et al. (2009). NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J. Clin. Invest. 119, 1251–1263.

Levy, E. M., Roberti, M. P., and Morど, J. (2011). Natural killer cells in human cancer: from biological functions to clinical applications. J. Biomed. Biotechnol. 2011, 676198. doi:10.1155/2011/676198

Li, J., Nandapopal, S., Wu, D., Romanuik, S. F., Paul, K., Thomson, D. J., et al. (2011). Activated T lymphocytes migrate towards cathode of DC electric fields in microfluidic devices. Lab Chip 11, 1298–1304.

Li, P. C., and Harrison, D. J. (1997). Transport, manipulation, and reaction of biological cells on-chip using electrokinetic effects. Anal. Chem. 69, 1564–1568.

Li, X., Wu, Z., Fu, X., and Han, W. (2013). A microRNA component of the neoplastic microenvironment: microregulators with far-reaching impact. Biomed. Res. Int. 2013, 762183.

Lin, F., Nguyen, C. M., Wang, S. J., Saadi, W., Gross, S. P., and Jeon, N. L. (2004). Effective neutrophil chemotaxis is strongly influenced by mean IL-8 concentration. Biochem. Biophys. Res. Commun. 319, 576–581.

Liu, D., Song, L., Wei, J., Courtney, A. N., Gao, X., Marinova, E., et al. (2012). IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antitumor activity. J. Clin. Invest. 122, 2221–2233.

Liu, I., Zhang, N., Li, Q., Zhang, W., Kr, P., Leng, Q., et al. (2011). Tumor-associated macrophages recruit CCR6+ regulatory T cells and promote the development of colorerul cancer via enhancing CCRL20 production in mice. PLoS ONE 6, e19495. doi:10.1371/journal.pone.0019495

Liu, J. Y., Wu, Y., Zhang, X. S., Yang, J. L., Li, H. L., Mao, Y. Q., et al. (2007). Single administration of low dose cyclophosphamide augments the antitumor
effect of dendritic cell vaccine. Cancer Immunol. Immunother. 56, 1597–1604.
Lorenzi, S., Mattei, F., Sistigu, A., Bracci, L., Spadaro, F., Sanchez, M., et al. (2011). Type I IFNs control antigen retention and survival of CD8(alpha)+ dendritic cells after uptake of tumor apoptotic cells leading to cross-priming. J. Immunol. 186, 5142–5150.
Ma, C., Zhang, Q., Ye, J., Wang, F., Zhang, Y., Warsi, Z., Ashgharzadeh, et al. (2014). Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2. J. Exp. Med. 199, 1213–1221.
Michielsen, A. I., Hogan, A. E., Marty, J., Tosetto, M., Cox, F., Hyland, I. M., et al. (2011). Tumour tissue microenvironment can inhibit dendritic cell maturation in colorectal cancer. Proc. Natl. Acad. Sci. 108, 26294–26294.
Michielsen, A. I., Ryan, E. J. I., and O’Sullivan, J. N. (2012). Dendritic cell infection correlates with survival of colorectal cancer patients on bevacizumab treatment. Oncotarget 1, 1445–1447.
Miescher, S., Schreyer, M., Barras, C., Capasso, F., and Poldrè, V. (1990). Sparse distribution of gamma/delta T lymphocytes around human epithelial tumours, predominantly infiltrated by primed/memory T cells. Cancer Immunol. Immunother. 32, 81–87.
Milush, J. M., Long, B. R., Snyder-Cappione, J. E., Cappione, A. J. III, York, V. A., Nahlová, L. C., et al. (2009). Functionally distinct subsets of human NK cells and monocyte/DC-like cells identified by coexpression of CD56, CD7, and CD4. Blood 114, 4823–4831.
Minato, N., Reid, L., and Bloom, B. R. (1981). On the heterogeneity of murine natural killer cells. J. Immunol. 154, 750–762.
Mitchem, J. B., Brennan, D. J., Knollhoff, B. L., Belt, A. B., Zhu, Y., Sanford, D. E., et al. (2012). Targeting tumour-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression and improves chemotherapeutic response. Cancer Res. 72, 4173–4183.
Morandi, B., Mortara, L., Chiossone, L., Accolla, R. S., Mingari, M. C., Moretta, L., et al. (2012). Dendritic cell editing by activated natural killer cells results in a more protective cancer-specific immune response. PLoS ONE 7(3), e39170. doi:10.1371/journal.pone.0039170
Moretta, A. (2002). Natural killer cells and dendritic cells: rendezvous in aborted tissues. Nat. Rev. Immunol. 2, 957–964.
Moretta, L., Ferlazzo, G., Bottino, C., Vitale, M., Pende, D., Mingari, M. C., et al. (2006). Effector and regulatory events during natural killer-dendritic cell interactions. Immunol. Rev. 214, 219–228.
Nagato, K., Motohashi, S., Ishibashi, F., Okita, K., Yamasaki, K., Moriya, Y., et al. (2012). Accumulation of activated in-vitro natural killer T cells in the tumor microenvironment after alpha-galactosylceramide-pulsed antigen presenting cells. J. Immunol. 32, 1071–1081.
Naito, Y., Saito, K., Shiiba, K., Ohuchi, A., Saigeni, K., Nagura, H., et al. (1998). CD8+ T cells infiltrated within cancer cells act as a prognostic factor in human colorectal cancer. Cancer Res. 58, 3491–3494.
Nakagawa, R., Serizawa, I., Motoki, K., Sato, M., Ueno, H., Iijima, R., et al. (2000). Antitumor activity of alpha-galactosylceramide, KRN7000, in mice with the melanoma B16 hepatic metastasis and immunohistological study of tumor infiltrating cells. Oncol. Res. 12, 51–58.
Osada, T., Nagawa, H., and Shibata, Y. (2004). Tumor-infiltrating effector cells of alpha-galactosylceramide-induced antitumor immunity in metastatic liver tumor. J. Immunol. Based Ther. Vaccines 2, 7.
Pardo, J., Aguilo, J. I., Anel, A., Martin, P., Joeckel, L., Borner, C., et al. (2009). The biology of cytotoxic T cell granule exocytosis pathway: granymes have evolved to induce cell death and inflammation. Microbes Infect. 11, 452–459.
Pardoll, D. (2003). Does the immune system see tumors as foreign or self? Annu. Rev. Immunol. 21, 807–839.
Park, B. G., Park, C. J., Yoon, C. H., Jang, S., Chi, H. S., Ryu, M. H., et al. (2012a). The extended leukocyte differential counting using the cytoid flow cytomteric system reveals that higher CD16+ cytotoxic NK+ T lymphocyte levels predict superior survival outcomes in patients with metastatic carcinoma. Cytomtery B Clin. Cytom. doi:10.1002/cytb.21063
Park, H. J., Kusnadi, A., Lee, J. E., Kim, W. W., Cho, B. C., Lee, J. I., et al. (2012b). Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors. Cell. Immunol. 278, 76–83.
Park, M. H., Lee, J. S., and Yoon, J. H. (2012c). High expression of CXCL3L1 by tumor cells correlates with a good prognosis and increased tumor-infiltrating CD8+ T cells, natural killer cells, and dendritic cells in breast carcinoma. J. Surg. Oncol. 106, 386–392.
Penuelas, S., Anido, I., Prieto-Sanchez, R. M., Folch, G., Barba, J., Cuartas, L., et al. (2009). TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell 15, 315–327.
Preiffer, M., Seitz, G., Ruck, P., Mueller, C., Steine, A., Lang, P., et al. (2011). CD155 is involved in NK-cell mediated lysis of human hepatoblastoma in vitro. Front. Biosci. (Elite Ed.) 3, 1456–1466.
Pham-Nguyen, K. B., Yang, W., Saxena, R., Thang, S. N., Woo, S. L., and Chen, S. H. (1999). Role of NK and T cells in IL-12-induced anti-tumor response against hepatic colon carcinoma. Int. J. Cancer 81, 813–819.
Pietra, G., Manzini, C., Vitale, M., Balsamo, M., Ongio, E., Boitano, M., et al. (2009). Natural killer cells kill human melanoma cells with characteristics of cancer stem cells. Int. Immunol. 21, 793–801.
Pietra, G., Vitale, M., Moretta, L., and Minangi, M. C. (2012). How melanoma cells inactivate NK cells. Oncoimmunology 1, 974–975.
Pietrobon, S., Cerruti-Vicini, J., Damotte, D., Crozet, L., Viallard, V., Validire, P., et al. (2011). Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res. 71, 5412–5422.
Pollard, J. W. (2009). Trophic macrophages in development and disease. Nat. Rev. Immunol. 9, 259–270.
Preynat-Seauve, O., Schuler, P., Con- tassot, E., Beermann, F., Huard, B., and French, L. E. (2006). Tumor-infiltrating dendritic cells are potent antigen-presenting cells able to activate T cells and mediate tumor rejection. J. Immunol. 176, 61–67.
Querzada, S. A., Peggs, K. S., Simp- son, T. R., and Allison, J. P. (2011). Shifting the equilibrium in cancer immunoeediting: from tumor toler- ance to eradication. Immunol. Rev. 241, 104–118.
Quintana, E., Shackleton, M., Sabel, S. M., Fullen, D. R., Johnson, T. M., and Morrison, S. I. (2008). Effi- cient tumour formation by single human melanoma cells. Nature 456, 593–598.
Ren, S., Johnson, B. G., Kida, Y., Ip, C., Davidson, K. C., Lin, S. L., et al. (2013). LRP-6 is a coreceptor for multiple fibrogenic sig- naling pathways in pericytes and myofibroblasts that are inhibited by DKK-1. Proc. Natl. Acad. Sci. U.S.A. doi:10.1073/pnas.1211179110.
Robert, M. P., Mordoh, J., and Levy, E. M. (2012a). Biological role of NK cells and immunother- apeutic approaches in breast
Sengupta, A., and Cancelas, J. A. (2010). Schumacher, K., Haensch, W., Roe-Schwarz, E. C., Qu, B., and Hoth, Schlecker, E., Stojanovic, A., Eisen, Sakuishi, K., Apetoh, L., Sullivan, J. Frontiers in Oncology | Tumor Immunity

2010 in understanding melanoma propagation. Mol. Oncol. 4, 451–457. Shurin, M. R., Shurin, G. V., Lokshin, A., Yurkovetsky, Z. R., Gutkin, D. W., Chatta, G., et al. (2006). Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies? Cancer Metastasis Rev. 25, 333–356. Simpson, K. D., Templeton, D. J., and Cross, J. V. (2012). Macrophage migration inhibitory factor promotes tumor growth and metastasis by inducing myeloid-derived suppressor cells in the tumor microenvironment. J. Immunol. 189, 5533–5540. Sinha, P., Clements, V. K., and Ostrand-Rosenberg, S. (2005). Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J. Immunol. 174, 636–645. Siryan, W., Feng, Y., Lichuan, Z., Jiarui, W., Yingyan, W., Li, J., et al. (2009). Application of microfluidic gradient chip in the analysis of lung cancer chemotherapy resistance. J. Pharm. Biomed. Anal. 49, 806–810. Smyth, M. J., and Godfrey, D. I. (2000). NK cells and tumor immunity—a double-edged sword. Nat. Immunol. 1, 459–460. Solinas, G., Gennaro, G., Mantovani, A., and Allavena, P. (2009). Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J. Leukoc. Biol. 86, 1065–1073. Solito, S., Falusi, E., Diaz-Montero, C., Donu, A., Pinton, L., Rosato, A., et al. (2011). A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood 118, 2254–2265. Srivastava, A. K., Sharma, R. K., Yolcu, E. S., Ulker, V., Macleod, K., Dinc, G., et al. (2012). Prime-boost vaccination with SA-4-1BBL costimulatory molecule and survivin as a therapeutic strategy in CD4+ T cells in human advanced colorectal carcinomas. J. Immunol. 187, 515–520. Tham, M., Wai, L. E., et al. (2012). STAT3 regulates tumor cell migration inhibitory factor production and myeloid cells are associated with the presence of activated myeloid-derived suppressor cells in the tumor microenvironment. J. Immunol. 189, 5533–5540. Toh, B., Chew, V., Dai, X., Khoo, K., Thom, M., Wai, L. E., et al. (2012). Immune predictors of cancer progression. Immunol. Rev. 239, 229–234. Turnquist, H. R., Lin, X., Ashour, A. E., Hollingsworth, M. A., Singh, R. K., Talmadge, J. E., et al. (2007). CCL21 induces extensive intratumoral immune cell infiltration and specific anti-tumor cellular immunity. J. Immunol. 189, 631–639. Van Ginderachter, J. A., Movahedi, H., Hassanzadeh Ghassabeh, G., Meerschaert, S., Beschon, A., Raes, G., et al. (2006). Classical and alternative activation of mononuclear phagocytes: picking the best of both worlds for tumor promotion. Immunobiology 211, 487–501. van Houdt, I. S., Sluijter, B. J., Moesbergen, L. M., Vesely, M. D., Kershaw, M. H., Schreiber, R. D., and Smyth, M. J. (2011). Nat- Immunol. 53, 64–72. van Houdt, I. S., Sluijter, B. J., Moesbergen, L. M., Vesely, M. D., Kershaw, M. H., Schreiber, R. D., and Smyth, M. J. (2011). Nat- Immunol. 53, 64–72. Van Kaer, L. (2007). NK cells: T lymphocytes and natural killer cells. Annu. Rev. Immunol. 25, 354–364. Vasquez-Dundidel, D., Pan, F., Zeng, Q., Gorbsoumov, M., Albesiano, E., Fu, J., et al. (2013). STAT3 regulates arginase-1 in myeloid-derived suppressor cells from cancer patients. J. Clin. Invest. doi:10.1172/JCI60808. Velthuis, J. H., Stitzinger, M., Aalbers, R. I., De Bont, H. J., Mulder, G. J., Kuppen, P. J., et al. (2003). Rat colon carcinoma cells that survived systemic immune surveillance are less sensitive to NK-cell mediated apoptosis. Clin. Exp. Metastasis 20, 713–721. Vesely, M. D., Kershaw, M. H., Schreiber, R. D., and Smyth, M. J. (2011). Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 29, 255–271. Vicari, A. P., Chiodoni, C., Vaure, C., Ait-Yahia, S., Dercamp, C., Mat- sos, E., et al. (2002). Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J. Exp. Med. 196, 541–549. Viola, A., Sarulahan, A., Bronte, V., and Molon, B. (2012). The pros and cons of chemokines in tumor immunologi- cal surveillance. Immunol. Rev. 233, 496–504. Vosvader, E. J., and Lindeman, G. J. (2008). Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 8, 755–768.
Wakita, D., Sumida, K., Iwakura, Y., Nishikawa, H., Ohkuri, T., Chamoto, K., et al. (2010). Tumor-infiltrating IL-17-producing gamma-delta T cells support the progression of tumor by promoting angiogenesis. *Eur. J. Immunol.* 40, 1927–1937.

Wang, X., Cui, Y., Luo, G., Wang, Q., Hu, J., He, W., et al. (2012a). Activated mouse CD4(+)Foxp3(-) T cells facilitate melanoma metastasis via Qa-1-dependent suppression of NK-cell cytotoxicity. *Cell Res.* 22, 1696–1706.

Wang, Y., Ma, Y., Fang, Y., Wu, S., Liu, L., Fu, D., et al. (2012b). Regulatory T cell: a protection for tumour cells. *J. Cell. Mol. Med.* 16, 425–436.

Ward, P. L., Koeppen, H. K., Hurteau, T., Rowley, D. A., and Schreiber, H. (1988). Signal transduction of gamma/delta T cell antigen receptor with a novel mitogenic anti-delta antibody. *Clin. Chem.* 34, 1476–1479.

Weigelin, B., Krause, M., and Friedl, P. (2011). Cytotoxic T lymphocyte migration and effector function in the tumor microenvironment. *Immunol. Lett.* 138, 19–21.

Weng, D., Song, B., Durfee, J., Sugiyama, V., Wu, Z., Koido, S., et al. (2011). Induction of cytotoxic T lymphocytes against ovarian cancerinitiating cells. *Int. J. Cancer* 129, 1990–2001.

Wilding, P., Pfahler, J., Bau, H. H., Zemel, J. N., and Kricka, L. J. (1994). Manipulation and flow of biological fluids in straight channels micromachined in silicon. *Clin. Chem.* 40, 43–47.

Wlodkowic, D., and Cooper, I. M. (2010). Tumors on chips: oncology meets microfluidics. *Curr. Opin. Chem. Biol.* 14, 556–567.

Wlodkowic, D., and Darzynkiewicz, Z. (2010). Microfluidics: emerging prospects for anti-cancer drug screening. *World J. Clin. Oncol.* 1, 18–23.

Wong, A. P., Perez-Castillejos, R., Christopher Love, J., and Whitides, G. M. (2008). Partitioning microfluidic channels with hydrogel to construct tunable 3-D cellular microenvironments. *Biomateri- als* 29, 1853–1861.

Wu, Y. J., Tian, W. T., Snider, R. M., Jacobs, M. K., Seibert, M. D., Ginsburg, A. C., et al. (2008). Antagonistic roles of CD4+ and CD8+ T-cells in 7,12-dimethylbenz(a)anthracene cutaneous carcinogenesis. *Cancer Res.* 68, 3924–3930.

Xia, J., Chen, X., Zhou, C. Z., Li, Y. G., and Peng, Z. H. (2011). Development of a low-cost magnetic microfluidic chip for circulating tumour cell capture. *JET Nanobiotecnol.* 5, 114–120.

Yasuda, H., Aritaka, N., Ando, J., Hiram, M., Komatsu, N., and Hirano, T. (2011). Chronic myelogenous leukemia with mild basophilia as the predominant manifestation at presentation. *Intern. Med.* 50, 501–502.

Ye, X. Z., Yu, S. C., and Bian, X. W. (2010). Contribution of myeloid-derived suppressor cells to tumor-induced immune suppression, angiogenesis, invasion and metastasis. *J. Genet. Genomics* 37, 423–430.

Yu, X., Li, H., and Ren, X. (2012). Interaction between regulatory T cells and cancer stem cells. *Int. J. Cancer* 131, 1491–1498.

Yusuf, N., Nasti, T. H., Katiyar, S. K., Jacobs, M. K., Seibert, M. D., Ginsburg, A. C., et al. (2008). Antagonistic roles of CD4+ and CD8+ T-cells in 7,12-dimethylbenz(a)anthracene cutaneous carcinogenesis. *Cancer Res.* 68, 3924–3930.

Zhang, L., Conejo-Garcia, J. R., Kat- saros, D., Gimotty, P. A., Massobrio, M., Regnani, G., et al. (2003). Intratumoral T-cells, recurrence, and survival in epithelial ovarian cancer. *N. Engl. J. Med.* 348, 203–213.

Zhang, Y., Lv, D., Kim, H. J., Kurt, R. A., Bu, W., Li, Y., et al. (2012). A novel role of hematopoietic CCL5 in promoting triple-negative mammary tumor progression by regulating generation of myeloid-derived suppressor cells. *Cell Res.* 23, 394–408.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 31 January 2013; accepted: 03 April 2013; published online: 17 April 2013.

Citation: Schiavoni G, Gabriele L and Mattei F (2013) The tumor microenvironment: a pitch for multipurpose players. *Front. Oncol.* 3:90. doi: 10.3389/fonc.2013.00090

This article was submitted to Frontiers in Tumor Immunity, a specialty of Frontiers in Oncology.

Copyright © 2013 Schiavoni, Gabriele and Mattei. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.